<?xml version='1.0' encoding='utf-8'?>
<document id="19900542"><sentence text="5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination."><entity charOffset="0-22" id="DDI-PubMed.19900542.s1.e0" text="5-Hydroxy-L-tryptophan" /><entity charOffset="99-108" id="DDI-PubMed.19900542.s1.e1" text="gaboxadol" /><pair ddi="false" e1="DDI-PubMed.19900542.s1.e0" e2="DDI-PubMed.19900542.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19900542.s1.e0" e2="DDI-PubMed.19900542.s1.e1" /></sentence><sentence text="The aim was to investigate the effect of 5-hydroxy-L-tryptophan (5-HTP) on gaboxadol pharmacokinetics in rats"><entity charOffset="41-63" id="DDI-PubMed.19900542.s2.e0" text="5-hydroxy-L-tryptophan" /><entity charOffset="65-70" id="DDI-PubMed.19900542.s2.e1" text="5-HTP" /><entity charOffset="75-84" id="DDI-PubMed.19900542.s2.e2" text="gaboxadol" /><pair ddi="false" e1="DDI-PubMed.19900542.s2.e0" e2="DDI-PubMed.19900542.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19900542.s2.e0" e2="DDI-PubMed.19900542.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s2.e0" e2="DDI-PubMed.19900542.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19900542.s2.e1" e2="DDI-PubMed.19900542.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s2.e1" e2="DDI-PubMed.19900542.s2.e2" /></sentence><sentence text=" As both 5-HTP and gaboxadol bind to the human proton-coupled amino acid transporter, hPAT1, a drug-drug interaction at the level of intestinal absorption might occur"><entity charOffset="9-14" id="DDI-PubMed.19900542.s3.e0" text="5-HTP" /><entity charOffset="19-28" id="DDI-PubMed.19900542.s3.e1" text="gaboxadol" /><entity charOffset="62-72" id="DDI-PubMed.19900542.s3.e2" text="amino acid" /><pair ddi="false" e1="DDI-PubMed.19900542.s3.e0" e2="DDI-PubMed.19900542.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19900542.s3.e0" e2="DDI-PubMed.19900542.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s3.e0" e2="DDI-PubMed.19900542.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19900542.s3.e1" e2="DDI-PubMed.19900542.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s3.e1" e2="DDI-PubMed.19900542.s3.e2" /></sentence><sentence text=" The in vitro transport of gaboxadol was measured across the hPAT1-expressing cell line Caco-2, and via the rat organic anion transporter, rOat1, in Xenopus oocytes pre-injected with rOat1 cRNA"><entity charOffset="27-36" id="DDI-PubMed.19900542.s4.e0" text="gaboxadol" /></sentence><sentence text=" The in vivo pharmacokinetic profile of gaboxadol after oral administration to rats was investigated in the absence and presence of a pre-dose of 5-HTP"><entity charOffset="40-49" id="DDI-PubMed.19900542.s5.e0" text="gaboxadol" /><entity charOffset="146-154" id="DDI-PubMed.19900542.s5.e1" text="5-HTP" /><pair ddi="false" e1="DDI-PubMed.19900542.s5.e0" e2="DDI-PubMed.19900542.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19900542.s5.e0" e2="DDI-PubMed.19900542.s5.e1" /></sentence><sentence text=" In Caco-2 cell monolayers &gt;80% of the absorptive gaboxadol transport was suggested to be hPAT1-mediated"><entity charOffset="50-59" id="DDI-PubMed.19900542.s6.e0" text="gaboxadol" /></sentence><sentence text=" In rats, the initial absorption rate of gaboxadol was decreased in the presence of 5-HTP"><entity charOffset="41-50" id="DDI-PubMed.19900542.s7.e0" text="gaboxadol" /><entity charOffset="84-92" id="DDI-PubMed.19900542.s7.e1" text="5-HTP" /><pair ddi="false" e1="DDI-PubMed.19900542.s7.e0" e2="DDI-PubMed.19900542.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19900542.s7.e0" e2="DDI-PubMed.19900542.s7.e1" /></sentence><sentence text=" The AUC of gaboxadol was increased by a factor of 3"><entity charOffset="12-21" id="DDI-PubMed.19900542.s8.e0" text="gaboxadol" /></sentence><sentence text="6-5" /><sentence text="5 when rats were pre-dosed with 5-HTP"><entity charOffset="32-40" id="DDI-PubMed.19900542.s10.e0" text="5-HTP" /></sentence><sentence text=" Gaboxadol was a substrate for the renal transporter rOat1 with a K(m)-value of 151 microM"><entity charOffset="1-10" id="DDI-PubMed.19900542.s11.e0" text="Gaboxadol" /></sentence><sentence text=" 5-HTP did not interact with rOat1"><entity charOffset="1-9" id="DDI-PubMed.19900542.s12.e0" text="5-HTP" /></sentence><sentence text=" In conclusion, gaboxadol acts as a substrate for hPAT1 and is a substrate of rOat1"><entity charOffset="16-25" id="DDI-PubMed.19900542.s13.e0" text="gaboxadol" /></sentence><sentence text=" In rats, 5-HTP decreased the initial absorption rate and increased AUC of gaboxadol"><entity charOffset="75-84" id="DDI-PubMed.19900542.s14.e0" text="gaboxadol" /><entity charOffset="10-18" id="DDI-PubMed.19900542.s14.e1" text="5-HTP" /><pair ddi="false" e1="DDI-PubMed.19900542.s14.e1" e2="DDI-PubMed.19900542.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s14.e1" e2="DDI-PubMed.19900542.s14.e0" /></sentence><sentence text=" 5-HTP thus had a significant impact on the pharmacokinetic profile of gaboxadol"><entity charOffset="71-80" id="DDI-PubMed.19900542.s15.e0" text="gaboxadol" /><entity charOffset="1-9" id="DDI-PubMed.19900542.s15.e1" text="5-HTP" /><pair ddi="false" e1="DDI-PubMed.19900542.s15.e1" e2="DDI-PubMed.19900542.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19900542.s15.e1" e2="DDI-PubMed.19900542.s15.e0" /></sentence><sentence text="" /></document>